Unity Biotechnology Inc
0.0 %
20.81 %
Yet to be announced
Company Overview
Unity Biotechnology is a biotechnology company focused on developing therapeutics to slow, halt, or reverse diseases of aging. The company's primary focus is on developing senolytic medicines that selectively eliminate senescent cells from diseased tissues. Their lead programs target age-related diseases of the eye, including age-related macular degeneration and diabetic macular edema.
Revenue Sources
Unity Biotechnology is a pre-revenue biotechnology company currently in R&D phase. The company reported zero revenue for all quarters examined. Since the company is pre-revenue and still in development stage, this criterion is not applicable at this time.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
The company is pre-revenue and in R&D phase. Interest expense was minimal or zero in most quarters, with only $97,000 reported in Q4 2023. Given the company's pre-revenue development stage, the interest metrics are not material to evaluate the core business model.
Operational Ethics
Based on review of company documents and public information, there is no evidence of significant ongoing associations with entities involved in human rights violations. The company's operations are primarily based in the United States, with no identified R&D centers or material business relationships in Israel or direct ties to the Chinese Communist Party.
Login to join the discussion